Skip to content New The AI buying guide for BD&L executives — now available on demand Watch
Resources

Latest thinking

Scientific insights, BD frameworks, and the reasoning behind assessments — written for the people who have to defend the decision.
Featured · Scientific insight

Scientific insights: Why China Now Owns the Late-Stage IL-4R Pipeline

Chinese companies now run seven of the eight IL-4Rα assets in Phase III — and the eighth is licensed to China too, with MG-K10’s latest Phase III data (94.3% EASI-75 at week 52) showing exactly why this comp set can’t be ignored. The unmet need is real. Even with three approved biologics, roughly half of SLE patients hit a meaningful composite response at one year, and sustained remission is rare. TLR7 sits genetically upstream of the interferon axis that drives ~75% of disease — a clean, well-validated target.

Scientific insights
Blog

Strategy & Due Diligence in Pharma Business Development

Pharma growth depends on smarter BD decisions. This article outlines a clear framework to evaluate external opportunities before committing to formal diligence. Blog
Blog

Why BD teams cannot afford to lose their memory & how AI can help

Even with databases, access to prior knowledge in biotech BD teams often breaks down. The antidote is simple : build durable organizational memory. AI can help. Blog
Blog

From overwhelm to clarity: prioritizing assets with AI-powered confidence

Facing a flood of biopharma assets? Learn how AI can help your BD team cut through the noise, gain confidence, and act with purpose. Blog
Blog

Modern biopharma BD: How to find the diamonds in the rough

Learn how top biopharma BD teams find diamonds in the rough by prioritizing strategic clarity, disciplined pipeline triage, and AI-powered asset tracking. Blog
Blog

Navigating pharma strategy and portfolio prioritization: A Q&A

With capital markets in flux, regulatory headwinds, and scientific risks, boards and executives must navigate pharma strategy and portfolio prioritization. Blog
Blog

Lessons from a pioneer in pharmaceutical decision-making

Jay Andersen, a pioneer in pharmaceutical decision-making, shared lessons learned from developing portfolio management and probability assessment approaches. Blog
Blog

Biopharma BD&L: the tsunami is upon us

Pharma’s business development and licensing (BD&L) teams are at the forefront of identifying new science to support their company’s future. Blog
Blog

Improving biopharma BD with AI-powered due diligence

In biopharma business development, companies face increasing pressure to identify the next blockbuster drug with limited resources and time constraints. Blog
Blog

Pharma portfolio analytics in a gen AI world

I recently sat down with a Top 20 pharmaceutical company to discuss their goals and struggles for the year ahead and how pharma portfolio analytics fits in. Blog
Blog

Chinese biotechs & assets, a Q&A with Kanya Rajangam, MD, PhD

Recently, I had a conversation with Dr. Kanya Rajangam, to discuss current perceptions about Chinese biotech, opportunities, language challenges, and risks. Blog
Blog

The Great Disruption: how Chinese assets will reshape drug development

Chinese biopharma companies are at an inflection point, with rapid advances in science, know-how, and talent; these assets will reshape drug development. Blog
Blog

5 insights from JPM 2025

Based on JPM 2025, it’s safe to say that the biotech industry is experiencing a broad resurgence, with subtle yet significant disruption beneath the surface. Blog
Blog

AI for biopharma business development: finding the right assets faster

By combining human expertise with AI-powered analysis, we’re helping biopharma companies make faster, more informed business development decisions. Blog
Blog

3 key ways AI-powered analysis supports drug development

Artificial intelligence-powered pipeline analysis is emerging as a tool that can help teams make better, faster drug development decisions. Blog
Blog

5 guardrails you MUST implement when using AI in biopharma

Implementing guardrails for artificial intelligence (AI) in biopharma is crucial for ensuring effective, safe, and compliant use of this powerful technology. Blog
Blog

Biotech Limited Partners: learnings from investing in biotech venture capital funds

Limited Partners (LPs) are at the heart of the biotech funding ecosystem—these crucial players ignite the funding flywheel that drives biotech innovation. Blog
Blog

4 common use cases for an AI-powered drug pipeline analysis platform

Let’s explore the four most common use cases for an AI-powered drug pipeline analysis platform and how they support strategic decision-making in biopharma. Blog
Blog

What causes AI hallucinations & how Vibe Bio delivers results you can trust

Artificial Intelligence covers a range of algorithmic applications and outputs. Sometimes, AI hallucinates, so how does Vibe Bio deliver trustworthy outputs? Blog
Blog

How can pharmaceutical companies improve pipeline analysis?

In biopharma, pipeline analysis provides comprehensive insights into the lifecycle of drug candidates, from discovery through clinical trials to market launch. Blog
Blog

Enabling every cure for community matters: Our AI-powered journey

Vibe Bio is doing extraordinary work to change drug development: from funding next-generation therapies to helping others identify the highest potential cures. Blog
Blog

4 major disruptions to the hunt for new cures, and how AI can help

The pursuit of novel cures in the pharmaceutical industry has always been a challenging endeavor. However, within the last decade or so, the landscape has become even more complex and disruptive due to several key factors.  In this blog, we explore four major disruptions impacting the hunt for new cures and how artificial intelligence (AI)… Blog

Get the latest thinking as it publishes

"*" indicates required fields

This field is for validation purposes and should be left unchanged.